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Abstract
Background: Intermediary filaments are involved in cell motility and cancer progression. In a
variety of organs, the expression of distinct intermediary filaments are associated with patient
prognosis. In this study, we seeked to define the prognostic potential of cytokeratin and vimentin
expression patterns in squamous cell carcinomas (SCC's) of the oral cavity.
Methods: 308 patients with histologically proven and surgically treated squamous cell carcinomas
of the oral cavity were investigated for the immunohistochemical expression of a variety of
intermediary filaments including high- and low-molecular weight cytokeratins (Ck's), such as Ck 5/
6, Ck 8/18, Ck 1, CK 10, Ck 14, Ck 19 and vimentin, using the tissue microarray technique.
Correlations between clinical features and the expression of Cytokeratins and vimentin were
evaluated statistically by Kaplan-Meier curves and multivariate Cox regression analysis.
Results: The expression of Ck 8/18 and Ck 19 were overall significantly correlated with a poor
clinical prognosis (Ck 8/18 p = 0.04; Ck19 p < 0.01). These findings could also be reproduced for
Ck 8/18 in primary nodal-negative SCC's and held true in multivariate-analysis. No significant
correlation with patient prognosis could be found for the expression of the other cytokeratins and
for vimentin.
Conclusion: The expression of Ck 8/18 in SCC's of the oral cavity is an independent prognostic
marker and indicates a decreased overall and progression free survival. These results provide an
extended knowledge about the role of intermediary filament expression patterns in SCC's.
Background
Intermediary filaments, like cytokeratins are essential
intracellular components, underlying or reflecting distinct
cellular properties and differentiation stages in epithelial
organs. The proteins of the cytokeratin family are epithe-
lium specific expressed [1] as low and high-molecular
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weight, resp. acid and basic polypeptides. Squamous,
stratified epithelium is usually characterized by the
expression of CK 5, which is found mainly in the basal cell
layers and Ck 5 is associated with the proliferative poten-
tial of these cells [2,3]. The intermediary cell layers show
an additional expression of Ck's 1 and 10, which are
regarded as signs of cellular differentiation [2]. In con-
trast, glandular epithelia reveal the expression of low-
molecular weight cytokeratins Ck's 8/18 and 19 as typical
features – expression pattern of Ck 8/18 is rather uncom-
mon in mature squamous epithelium. Ck 19 expressed
heterogeneously in the basal cell layers of stratified squa-
mous epithelium [2,3]. Suprabasal expression of Ck 19
seems to be correlated with premalignant transformation
in oral epithelium [4]. The expression of vimentin is
mainly regarded as sign of a mesenchymal differentiation.
However, vimentin-positively has repeatedly reported in
various carcinomas and was interpreted as sign of an epi-
thelial-mesenchymal transition, indicating an increased
metastatic potential [5-9].
Recently, it could be shown that the induction of Ck 8/18
expression in non-malignant buccal mucosa cells resulted
in a significant change of phenotypic characteristics after
Ck 8/18 transfection [10]. These changes included an
increased cellular motility, which might give first hints for
an increased tumour aggressiveness and poor patient
prognosis. However, these findings have not been trans-
ferred on a clinical level, yet. Therefore, the significance of
these findings in a clinical context, especially in regard to
the prognostic importance is unclear.
It was therefore the aim of this study to evaluate the
expression of intermediary filaments in SCC's in relation
to clinico-pathological features, especially for prognostic
purposes by the use of tissue micro arrays and immuno-
histochemistry.
Methods
Patients with histologically proven squamous cell carci-
noma of the oral floor treated surgically were eligible for
the study. All patients underwent surgical treatment
including radical resection of the whole tumour with a
free histopathological margin of at least 4 mm from the
tumour borders. Selective neck dissection of Level I, II, III
and V was performed in case of suspect results in preoper-
ative tumourstaging by computertomography or sonogra-
phy examination or in case of tumour size over 2 cm,
bilateral selective neck dissection was performed when the
tumour spread the midline (according to the recommen-
dation of Robins et al. 2002 [11]). Radiotherapy was per-
formed when lymph node metastases were detected
histologically. All tumours were classified postsurgically
according to the TNM system 6th eds. UICC 2002 [12].
Method
Tumour specimens of 308 patients were investigated for
the expression of Ck 5/6, Ck 8/18, Ck 1, CK 10, Ck 14, Ck
19 and vimentin (Table 1) by means of the tissue micro
array (TMA) technique.
For tissue micro array (TMA) construction, two punch
biopsies with a diameter of 0.6 mm from each donor
block were taken and transferred into the new acceptor
block. TMA construction was performed by using a special
tissue micro array instrument (Beecher Instruments, New
Jersey, USA), according to standard protocols [13,14].
Immunohistochemistry was performed on 4-µm-thick
TMA sections. After deparaffinization and rehydration,
endogenous peroxidase activity was blocked for 30 min-
utes in methanol containing 0.3% hydrogen peroxide.
After antigen retrieval, a cooling-off period of 20 minutes
preceded the incubation of the primary antibody. Thereaf-
ter, the catalyzed signal amplification system (DAKO,
Glostrup, Denmark) was used for Ck 5/6, Ck 8/18, Ck 1,
CK 10, Ck 14, Ck 19 and vimentin staining according to
the manufacturer's instructions.
All antibodies were detected by a standard avidin-biotin
complex method with a biotinylated rabbit anti-mouse
antibody (DAKO) and an avidin-biotin complex (DAKO).
The stainings were developed with diaminobenzidine or
alternatively using LSAB/AP (DAKO). Before the slides
were mounted, all sections were counterstained for 45 sec-
onds with hematoxylin and dehydrated in alcohol and
xylene. Appropriate negative controls (obtained by omis-
Table 1: Antibodies, company, clone, pre-treatment and dilution of used antibodies.
Antibody Company Clone Pre-treatment Dilution
Ck 5/6 DAKO, Glostrup, Denmark D5/16B4 Autoclave 10 min 1 : 80
Ck 8/18 Dianova, Hamburg, Germany K8.8/DC10 Autoclave 10 min, citrate buffer 1 : 40
Ck 1 Novocastra, Newcastle, UK 34βB4 Steamer 30 min, citrate buffer 1 : 150
Ck 10 DAKO, Glostrup, Denmark DE-K10 Steamer 30 min, citrate buffer 1 : 400
Ck 14 Dianova Hamburg, Germany LL002 Steamer 30 min, citrate buffer 1 : 50
Ck 19 Quartett GmbH, Berlin, Germany KS19.1 Steamer 30 min, citrate buffer 1 : 80
Vimentin Ventana Inc., Tucson, USA V9 Steamer 30 min, citrate buffer 1 : 1000BMC Cancer 2006, 6:10 http://www.biomedcentral.com/1471-2407/6/10
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sion of the primary antibody) and positive controls were
used throughout.
The expression of Ck 5/6, Ck 8/18, Ck 1, CK 10, Ck 14, Ck
19 and vimentin were determined independently by two
pathologists (HB and JP). Both pathologists determined
the percentage of positive cells in each core.
The percentage was classified for Cytokeratin 19 in 3
groups (0 % no Expression, 1:1–50% moderate expres-
sion, 2 >50% high expression) and Ck 5/6, Ck 8/18, Ck 1,
CK 10, Ck 14 and vimentin in two groups (0: no Expres-
sion, 1: ≥1% positive expression). The mean percentage
value of the two cores representing one tumour and were
used for further evaluation.
Statistical analysis
The TNM-stage, the histological differentiation and the
expression of Ck 5/6, Ck 8/18, Ck 1, CK 10, Ck 14, Ck 19
and vimentin were related to the duration of the progres-
sion-free and the overall survival. The measurement of
time started from the date of surgery to the date of histo-
logically proven recurrent or metastatic carcinoma or dis-
ease related death, respectively. Patients who died from
intercurrent disease during the trial were censored at the
date of death. Patients lost to follow-up were censored at
the date of the last examination.
Correlations between clinical features and the expression
of cytokeratins were evaluated statistically by chi-square
tests. The overall survival curves were constructed accord-
ing to Kaplan and Meier [15]. The Log-Rank test was used
to assess differences between groups and the multivariate
survival analysis was performed with Cox regression [16],
a p-value < 0.05 was considered to be significant.
Results
The series comprised 308 patients (240 men and 68
women) with a median age of 58 years (range 31–90). All
tumours were classified post surgically according to the
TNM system [12]. Patients were clinically evaluated in our
routine follow-up for 3–10 years. Clinical and tumour
details of the patients with oral squamous cell cancer are
shown in Table 2.
On average 90 % of all cores could be evaluated for the
expression of intermediate filaments.
Immunohistochemical examination showed that Ck 8/
18, Ck 5/6, Ck 1, CK 10, Ck 14, Ck 19 and vimentin reac-
tivity was confined homogeneously to the cytoplasma of
neoplastic cells. The expression levels did not differ signif-
icantly for the vast majority of the cases between the two
tumour cores representing one case, indicating a rather
homogeneous expression. No correlation was found
between Ck 1, Ck 5/6, Ck 10, Ck 14, vimentin and the sur-
vival prognosis.
Detectable levels of Ck 8/18 (Ck 8/18 ≥ 1%) were found
in 54 % (154/287) of the oral SCCs. Detectable levels of
Ck 19 (Ck 19 ≥ 1%) were found in 37,5% (96/256) of the
cases, high levels of Ck 19 expression (Ck 19 > 50%) were
found in 4,2% (11/256) of the investigated tumour spec-
imens (Table 3). The immunohistochemical staining is
shown in Figure 1.
Ck 5/6 and Ck 14 were significantly correlated with the
tumour size and lymph node status in the Chi-square Test
(Table 4) and between each other (p < 0.01). No correla-
tion was found between tumour size, tumour differentia-
tion, lymph node status and the expression of Ck 8/18, Ck
1, Ck 10, Ck 19 and vimentin in Chi-square test.
Log-rank test of Ck 8/18 and Ck 19 expression showed a
significantly decreased overall survival of carcinomas with
a Ck 8/18 expression (Ck 8/18 ≥ 1% (n = 154), p < 0.04,
Table 4: Chi-square Test of Ck 5–6 and Ck 14
Prognosticator Node status P value Tumour size P value
Ck 5–6 0.045 0.026
Ck 14 0.021 0.037
Table 2: Tumour patient cases in this study
Age (mean) 58 years (range 31 – 90 years)
Sex 240 men, 68 women
Follow-up (mean) 64 months (range 4 – 181 months)
T stadium 135 T1 tumours
125 T2 tumours
15 T3 tumours
33 T2 tumours
N stadium 212 N0 lymph node negative
57 N1 lymph node positive carcinoma
39 N2 lymph node positive carcinoma
Grading 54 well differentiated tumours (G1)
214 moderately differentiated tumours (G2)
40 weakly differentiated tumours (G3)
Table 3: Expression profile of cytokeratins
Antibody No Expression postive Expression
CK 5/6 123 169
CK8/18 133 154
CK 1 147 121
CK 10 177 91
CK14 159 107
Ck 19 149 107
Vimentin 237 24BMC Cancer 2006, 6:10 http://www.biomedcentral.com/1471-2407/6/10
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Immunohistochemical staining of oral squamous cell carcinoma with cytokeratin cytokeratin antibodies Figure 1
Immunohistochemical staining of oral squamous cell carcinoma with cytokeratin cytokeratin antibodies. a) cytokeratin 5/6 Anti-
body (magnification 20×) b) cytokeratin 19 antibody (magnification 20×) c) cytokeratin 8/18 antibody (Magnification 10×) d) 
cytokeratin 8/18 antibody (magnification 20×) e) cytokeratin 14 antibody (magnification 20×) d) cytokeratin 14 antibody (mag-
nification 20×).
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Fig. 2) and a significant decreased overall survival associ-
ated with increased expression level of CK 19 (CK 19< 1%
(n = 149), Ck 19 = 1–49% (n = 96), Ck 19 >50% (n = 11),
p < 0.01, Fig. 3)
In the subgroup of node negative oral squamous cell can-
cer the expression of Ck 8/18 and the high expression of
Ck 19 were also correlated with a poor overall survival (Ck
8/18, p < 0,04, Fig. 4) (Ck 19, p < 0.01). No influence of
vimentin coexpression on the overall survival prognosis
of Ck 8/18 and Ck 19 positive carcinomas was observed.
All carcinomas with an expression of Ck 8/18 and Ck 19
were reviewed and re-evaluated on whole sections. This
was done in order to exclude the possibility of a misinter-
pretation and misclassification of dedifferentiated salivary
gland carcinomas as poorly differentiated SCC's. How-
ever, in all these tumours the diagnosis of a primary sali-
vary gland carcinoma could be ruled out.
In multivariate Cox analysis we compared the overall sur-
vival according to clinically established prognostic factors
tumour size and nodal status with the expression of Ck 8/
18, Ck 5/6, Ck 1, CK 10, Ck 14 and Ck 19 (Table 5). Three
parameters as nodal status, tumour size and Ck 8/18
expression were indicated by Cox regression as independ-
ent predictors of survival prognosis.
Discussion
Intermediate filaments are central components of the
intracellular skeleton. The expression of distinct interme-
diate filament proteins is tissue-specific and almost highly
conserved during carcinogenesis. Intermediate filaments
are interpreted as mere bystanders and markers of distinct
intracellular, cell-specific regulation mechanisms. Several
studies associated changes in intermediate filament
expression with an altered cellular behaviour [17,18].
The expression of high molecular weight cytokeratins,
especially Ck 5 is a hallmark of squamous epithelium and
is predominantly seen in the basal layers of stratified epi-
thelium [2,19]. This cell layer is regarded as the anatomi-
cal localization of tissue specific stem/progenitor cells.
Stem cells of stratified epithelium have been repeatedly
described as the major cellular targets for cancer causing
mutations and therefore might give in a long term rise to
the development of SCC's. In the context of the existing
literature it seems logical that SCC's retain and are pheno-
Overall survival of patient with oral squamous cell carcinoma  in dependence on Cytokeratin 19 expression calculated by  the Kaplan-Meier method Figure 3
Overall survival of patient with oral squamous cell carcinoma 
in dependence on Cytokeratin 19 expression calculated by 
the Kaplan-Meier method.
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Overall survival of patient with oral squamous cell carcinoma  in dependence on Cytokeratin 8–18 expression calculated by  the Kaplan-Meier method Figure 2
Overall survival of patient with oral squamous cell carcinoma 
in dependence on Cytokeratin 8–18 expression calculated by 
the Kaplan-Meier method.
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typically characterized by the expression of Ck 5. Adult
healthy non-keratinizing stratified squamous epithelium
of the upper aerodigestive tract express Ck 19 in basal lay-
ers but normally do not express Ck 8/18 [19]. Typical
glandular cytokeratin Ck 8/18 are normally not expressed
in SCC's [2,4]. On the other hand, Ck 8 and 18 is
expressed in fetal buccal mucosa and tongue epithelium
till 27 weeks of gestation [20].
Our study shows in a series of more than 300, uniformly
treated, primary SCC's of the oral cavity that the expres-
sion of glandular cytokeratins such as Ck 8, 18 and 19,
pinpoints a significant subgroup of SCC's. These carcino-
mas were associated with a poor prognosis, independ-
ently of the primary, preoperative lymph node status. It is
important to stress that this held also true in multivariate
analysis. This might be surprising on a first glance, since
recent other clinico-pathological studies in SCC's of the
oral cavity, especially with the focus on Ck 19 revealed
inhomogeneous results [21-24]. This might on the one
hand be due to significantly lower numbers of investi-
gated tumour samples, and on the other hand caused by
different techniques for the determination for the expres-
sion of cytokeratins 8/18 and 19 on the RNA and protein
level. However, similar results to our findings have also
been reported for skin carcinomas. Nevertheless, recent
cell culture and studies with chemical carcinogens
strongly support our results and revealed an important
role of CK 8/18 in various steps of the pathogenesis and
progression of SCC's. A spontaneous induction of Ck's 8
and 18 expression could be shown in SV40T-immortal-
ized buccal mucosa cells, in tobacco induced leukoplakias
and after introduction of v-H-Ras in epidermal mouse
keratinocytes [25]. The transfection of buccal mucosa cells
with a vector for Ck 8/18 resulted additionally in a signif-
icantly altered cellular morphology and increased cell
motility – features associated with or being prerequisites
for invasive tumour behaviour [10]. This was in line with
previous experiments in melanoma cells [26]. The
involvement of Ck 8/18 in SCC progression could further
be demonstrated in chemically induced SCC's in the
mouse skin. Whereas SCC's in mouse epidermis were Ck
8/18 positive, non-invasive papillomas did not show this
feature. However, the underlying disturbed intra- and
extra cellular regulation mechanisms have been character-
ized not in detail yet. A central role for TGF-alpha via the
Epidermal Growth Factor Receptor (EGFR) has been pos-
tulated [27,28]. In contrast, the induction of Ck 8/18
expression in a similar experimental setting has also been
described for TGF-alpha deficient mice, with putative
involvement of H-Ras [29]. In consequence, multiple
Table 5: Multivariate analysis of the time of survival in relation to the Cytokeratins expression and other prognostic factors
Prognosticator P valuea RRb Confidance intervalc
Tumor size *0.036 1.239 1.0–1.5
Nodal status *0.000 1.866 1.4–2.4
CK5/6 0.350 1.167 0.8–1.6
CK1 0.931 0.985 0.7–1.4
CK10 0.852 0.968 0.7–1.4
CK19 0.227 1.163 0.9–1.5
CK14 0.470 0.872 0.6–1.3
CK8/18 *0.024 1.487 1.1–2.1
a The partially nonparametric regression model of Cox (1972) was used to evaluate the predictive power of vatious combinations of 
prognosticators in a multivariate manner.
b RR, relative risk
c 95% confidence interval
Overall survival of patient with nodal negative oral squamous  cell carcinoma in dependence on Cytokeratin 8–18 expres- sion calculated by the Kaplan-Meier method Figure 4
Overall survival of patient with nodal negative oral squamous 
cell carcinoma in dependence on Cytokeratin 8–18 expres-
sion calculated by the Kaplan-Meier method.
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pathways in the regulation of Ck 8/18 are conceivably
existing.
In general, cytokeratin expression patterns are highly-con-
served. The above mentioned data from the literature
showed that any change in the intermediate filament
expression pattern reflects or underlies changes in sub-
stantial cellular properties. Strong homologies could also
be shown in other carcinomas. In primary breast cancer,
this could be demonstrated with different approaches.
Down-regulated expression of cytokeratin Ck 8/18 was
associated with increased metastatic properties and poor
prognosis in breast cancer [30]. The expression of Ck 5 in
a small subset of invasive breast cancers was in contrast
associated with a poor prognosis [31].
Interestingly, the expression of vimentin, alone or in com-
bination with Ck 8/18 and 19, was not associated with
poor prognosis or higher tumour stages. A multitude of
studies gave evidence that the expression of vimentin in
carcinomas has to be interpreted as a sign of an epithelial-
mesenchymal transition, associated with high tumour
aggressiveness [9,32]. This association remains questiona-
ble, since the expression of vimentin has already been
described in non-invasive premalignant lesions of squa-
mous epithelium and cultured keratinocytes.
Finally, from a clinical point of view, our results show that
the determination of the Cytokeratin 8–18 and 19-expres-
sion in SCC of the oral cavity harbours a significant prog-
nostic potential. Our results seem to define subgroups of
high-risk patients who might benefit from more intensive
therapy or new therapeutic strategies like Cytokeratin 19
antibodies [33]. For human ovarian adenocarcinoma cells
it could be shown that cytokeratins 18 could sensitize
these cells to cisplatin [34]. These results demonstrate that
modulating the expression of an intermediate filament
protein results in sensitization to chemotherapeutic
drugs. The subgroup of ck 8–18 positive squamous cell
carcinoma may have a benefit by chemotherapy with cis-
platin. Further investigations are necessary to determine
the clinical impact of these hypotheses.
Conclusion
In conclusion, our results in a series of 308 primary, pre-
viously untreated SCC's of the oral cavity showed an
important prognostic impact for the expression of glandu-
lar, simple cytokeratins in SCC's. Further studies have to
unravel the underlying regulatory changes in order to
allow the definition of specific therapies of these high risk
cancer patients.
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